Emicizumab is a recombinant humanized bispecific monoclonal antibody mimicking the cofactor function of activated factor VIII.
| INTRODUC TI ON
Haemophilia A is a lifelong bleeding disorder characterized by a congenital deficiency or dysfunction of factor VIII (FVIII). The standard of care for patients with severe haemophilia A without neutralizing antibodies against FVIII ('FVIII inhibitors') is intravenous administration of FVIII products. 1 However, despite the regular prophylaxis with FVIII given once or more times per week, the majority of patients are still at the risk of bleeding. 2, 3 Frequent intravenous infusions and vascular access are burdensome, particularly for paediatric patients and their caregivers. Moreover, FVIII inhibitors develop in up to approximately 30% of patients with severe haemophilia A receiving FVIII, 4, 5 which renders FVIII products ineffective and complicates treatment of such patients. Emicizumab (HEMLIBRA ® ; Chugai Pharmaceutical Co., Ltd.) is a recombinant humanized bispecific monoclonal antibody that binds to factor IX, activated factor IX (FIXa), factor X (FX) and activated factor X to, by bridging FIXa and FX, mimic the cofactor function of activated FVIII. 6 In adult and adolescent patients with or without inhibitors, clinically meaningful efficacy of emicizumab for bleeding prevention was demonstrated with a subcutaneous maintenance dose of 1.5 mg/kg every week (QW) in the HAVEN 1 and HAVEN 3 studies, 7, 8 and similar efficacy profiles were confirmed with less frequent subcutaneous maintenance doses of 3 mg/kg every 2 weeks (Q2W) and 6 mg/kg every 4 weeks (Q4W) in the HAVEN 3 and HAVEN 4 studies, respectively. 8, 9 Another study (HAVEN 2) was conducted in paediatric patients with inhibitors. 10 However, there was no clinical experience of emicizumab in paediatric patients without inhibitors.
The HOHOEMI study reported herein is the first study for emicizumab in paediatric patients without inhibitors, in which we evaluated the efficacy, safety and pharmacokinetics of the Q2W and Q4W regimens of emicizumab.
| MATERIAL S AND ME THODS
This study was conducted at four centres in Japan, beginning in October 2017, in compliance with the Declaration of Helsinki and the ICH Guideline for Good Clinical Practice. The study protocol was approved by the institutional review board at each centre. Patients' legally authorized representatives provided written informed consent for study participation, and patients aged 3 years or older provided assent where possible. This study was registered at http:// www.clini caltr ials.jp (JapicCTI-173710).
| Patients
Eligible participants were <12 years old weighing over 3 kg and had severe congenital haemophilia A without FVIII inhibitors. Patients tested negative for inhibitors (<0.6 BU/mL) within the 8 weeks prior to enrolment. Documentation of bleeding episodes and treatment with coagulation factors (including confirmation of no history of treatment with coagulation factors) was required for the 12 weeks prior to enrolment for patients <2 years old and for the 24 weeks prior to enrolment for patients ≥2 years old. Key exclusion criteria included complication of a bleeding disorder other than congenital haemophilia A, thromboembolic diseases within the past 12 months and high risk of thrombotic microangiopathy (TMA) based on previous or familial history of TMA (eg thrombotic thrombocytopenic purpura, atypical haemolytic uraemic syndrome).
| Study design
This multicentre, open-label, non-randomized study was designed to evaluate the efficacy, safety and pharmacokinetics of emicizumab administered subcutaneously at a maintenance dose of 3 mg/kg Q2W or 6 mg/kg Q4W in paediatric patients with haemophilia A without inhibitors. Both the Q2W and Q4W cohorts received a loading dose of 3 mg/kg QW subcutaneously for the first 4 weeks before maintenance dosing ( Figure 1 ). We planned for a minimum of six patients to be enrolled in each cohort. Patient enrolment in the Q2W cohort preceded that in the Q4W cohort. Patients who had received FVIII prophylaxis prior to enrolment were permitted to continue FVIII prophylaxis until receiving the second loading dose of emicizumab. FVIII products were administered for breakthrough bleeding as necessary.
F I G U R E 1 Study design. QW, every week; Q2W, every 2 weeks; Q4W, every 4 weeks. The study design is open-label, non-randomized. Patients in the Q4W cohort were enrolled after the completion of enrolment in the Q2W cohort. a Patients who experienced ≥2 bleeding events treated with coagulation factors during the last 8 wk of the first 12 wk of treatment were eligible for up-titrating the maintenance dose to 3 mg/kg QW. After the first 12 wk of treatment, patients who experienced ≥2 bleeding events treated with coagulation factors during any consecutive 12 wk were eligible for the dose up-titration. b Patients with sustained clinical benefit during the first 24 wk of treatment could continue emicizumab prophylaxis afterwards Patients who met the criteria for insufficient bleeding control after receiving emicizumab prophylaxis for at least 12 weeks were offered the opportunity to up-titrate the maintenance dose to 3 mg/kg QW.
| Outcome measures
Efficacy outcomes included annualized bleeding rates (ABRs) to evaluate the effects of emicizumab prophylaxis on bleeding frequency. The standardized definition of a bleeding event 11 was applied (Appendix S1).
Caregivers were asked to record the types and durations of physical activities of patients for scheduled weeks. The types of activities were classified into three categories reflecting the risk of acute injury or collision (low, middle and high) that children could experience while participating in the activity. 12 Caregivers were also asked to indicate whether they preferred emicizumab prophylaxis over the patient's previous haemophilia treatment after the first 16 weeks of treatment; caregivers who preferred emicizumab were asked to select influencing factors and the top three factors in order of perceived importance (EmiPref survey 8 ).
Safety outcomes included adverse events (AEs), physical examination findings, vital signs and laboratory test abnormalities. Plasma emicizumab concentrations and anti-emicizumab antibody positivity were determined as previously described. 13, 14 
| Statistical analysis
The primary analysis was planned to be performed when the last patient had completed at least 24 weeks of treatment or was TA B L E 1 Baseline demographic and clinical characteristics Characteristics Q2W cohort (N = 6)
Q4W cohort (N = 7)
Age (y), median (range) 6.6 (1. Target joints were defined as joints in which at least three bleeding events had occurred within the 24 wk prior to enrolment; target joints were not identified in patients <2 y old owing to the lack of historical data collection on bleeding episodes and treatment with coagulation factors during the 24 wk prior to enrolment.
TA B L E 2 Model-based and calculated ABRs during emicizumab prophylaxis

Patients without bleeding, no. (%)
Patients with bleeding, no. (total number of bleeds)
Model-based ABRs a (95% CI)
Calculated ABRs b mean, median (range)
Q2W cohort, N = 6, median (range) efficacy period: 39.9 (37.9-41.4) wk 
| RE SULTS
| Study population
A total of 13 Japanese male paediatric patients with severe haemophilia A without inhibitors participated in this study, with 6 and 7 patients in the Q2W and Q 4W cohorts, respectively ( Table 1) week in one patient who refused frequent intravenous injection (Table   S1 ). Each cohort included one patient previously treated with immune tolerance induction (ITI) therapy (7.4 and 0.4 years before enrolment).
Only one patient in the Q2W cohort had a target joint.
As of the data cut-off date, all 13 patients were continuing emicizumab prophylaxis, and no patients had dose up-titration. The 
| Efficacy
During the on-treatment period, 2/6 patients in the Q2W cohort and 5/7 patients in the Q4W cohort, including a PUP aged 4 months, had no treated bleeds. In the Q2W cohort, two patients each had two treated bleeds and two patients each had one treated bleed. In the Q4W cohort, one patient had two treated bleeds and one patient had one treated bleed. Out of the six treated bleeds in the Q2W cohort, one treated bleed was a spontaneous joint bleed, and the other five treated bleeds were traumatic including three joint bleeds occurring in three patients. In the Q4W cohort, all three treated bleeds were traumatic and were not joint bleeds. All nine treated bleeding events were successfully managed by episodic treatment with FVIII; eight treated bleeding events were managed with a single dose of FVIII (32.5-64.7 IU/kg), and the other which occurred in a joint was managed with FVIII given once daily for 5 days (31.4-32.6 IU/kg).
One patient who had had a target joint (left knee) prior to enrolment had no bleeds at the joint. Model-based ABRs for treated bleeding events were 1.3 (95% confidence interval [CI], 0.6-2.9) and 0.7 (95% CI, 0.2-2.6) in the Q2W and Q4W cohorts, respectively ( Table 2 ).
For 5/6 patients in the Q2W cohort and all seven patients in the Q4W cohort, calculated ABRs for treated bleeding events in the ontreatment period decreased from those in the pretreatment period or remained at zero ( Figure S1 ). (work, school, sports and social interactions) was less' (from 3 caregivers, 23.1%; Figure 3 ).
Model-based
| Safety
All patients experienced at least one AE, and a total of 133 AEs were reported; 62 and 71 events in the respective Q2W and Q4W cohorts.
AEs that occurred in at least two patients are shown in Table 3 . The Three patients underwent minor surgeries without safety issues.
Two patients had one tooth extraction each; one patient was managed with a single preoperative preventative dose of FVIII (40.0 IU/kg), and the other patient was managed without preventative doses of FVIII.
Neither required FVIII treatment after the surgeries. One patient had removal of an implanted central venous port device with a single preoperative preventative dose of FVIII (64.9 IU/kg) and received a single postoperative preventative dose of FVIII (64.9 IU/kg) after the surgery. The results of the preference survey also supported the favourable characteristics of the Q2W and Q4W regimens of emicizumab.
| Pharmacokinetics and immunogenicity
The most frequent reason selected as the most important for the preference was that the frequency of treatments was lower, which was expected as a potential benefit from the long half-life and was in line with the results of HAVEN 3 and HAVEN 4. 16 The second most fre- indicating that the relationship between plasma emicizumab concentrations and ABRs reaches almost a plateau at above approximately 30 μg/mL 17 ; this appears similar to a reported relationship between FVIII activity and ABRs indicating that the risk of joint bleeds is minimized at 10-15 IU/dL and higher. 18 Taken together, these findings support the appropriateness of applying the Q2W and Q4W regimens in paediatric patients without inhibitors.
In this study, use of 2 anti-emicizumab idiotype monoclonal antibodies enabled measurement of FVIII inhibitors in plasma samples involving emicizumab. Alternative approaches include use of a chromogenic Bethesda assay with reagents containing bovine FIXa and FX, which is insensitive to and can avoid interference by emicizumab. 19 The main limitations to this study are the small numbers of patients in each cohort and the open-label, non-randomized, sequential-cohort study design, which make it difficult to obtain robust results of efficacy and safety profiles of emicizumab.
| CON CLUS ION
This study showed remarkable efficacy and favourable safety of the Q2W and Q4W regimens of emicizumab in children with severe haemophilia A without inhibitors, including a PUP aged 4 months. The emicizumab exposure observed in this study was within the variability observed in the preceding adult/adolescent studies. These results confirm the appropriateness of applying the Q2W and Q4W regimens of emicizumab in paediatric patients with haemophilia A without inhibitors.
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